ArticleBMC cancer2025
Risk factors for radiation-induced rib fractures following proton beam therapy for stage I non-small cell lung cancer: a retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Using Organoids to Unlock the Potential of Human Torpor for Spaceflight.Current stem cell reports · 2026Article
- Stereotactic radiotherapy for rib metastases from prostate cancer: A multicenter real-world analysis of local control, pain response, and treatment tolerance (RIBRISK).Therapeutic advances in medical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUnderstanding and managing radiation-induced adverse events is becoming increasingly important in hypofractionated radiotherapy due to the use of higher doses per fraction compared with conventional radiotherapy. Specifically, toxicities of hypofractionated proton and carbon-ion beam therapy are still unclear. We investigated the clinical, anatomical, and dosimetric risk factors for radiation-induced rib fractures (RIRFs) following passive-scattering proton beam therapy (PBT) for stage I non-small cell lung cancer (NSCLC).
methodsWe retrospectively investigated patients with stage I NSCLC who underwent PBT with 66-70 Gy (relative biological effectiveness [RBE]) in 10 fractions, completing a minimum follow-up of 36 months. Rib fractures were detected by follow-up chest computed tomography (CT) examination, independent of symptoms of thoracic pain. Dose-volume histograms of separately contoured ribs on planning CT images were calculated by the treatment planning system in a retrospective manner. Kaplan-Meier and Cox proportional hazards analyses were performed on individual ribs to identify significant risk factors associated with RIRF.
resultsAmong the 85 patients finally involved in this study, we identified 116 fractured ribs in 55 participants (64.7%). The 2- and 3-year frequencies of experiencing any RIRF were 36.5% and 52.9%, respectively. The median time-to-fracture was 23.5 months (range: 5-65). We used a total of 224 ribs irradiated over 50 Gy (RBE)-including all the detected fractured ribs-for statistical analysis. Univariate and multivariate analyses revealed the maximum-rib dose to a small volume, position of the maximum-dose point, bone mineral density, 1st rib number, and use of systemic corticosteroids to be related to the incidence of RIRFs.
conclusionsIn addition to dosimetric parameters, factors related to skeletal structure and bone strength are crucial predictors of proton RIRFs and should be considered for safer radiation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.